Patent ID: 7285552
Filing Date: 2007-10-23
Classification: A61K,A61P,C07D

Abstract:
1. A method for treatment of a disease selected from the group consisting of HIV infection, AIDS, and HIV infection acquiring multidrug resistance, which comprises administering to a subject in need thereof an effective amount of a triazaspiro[5.5]undecane compound represented by formula (I): wherein R (1) hydrogen, (2) C1-18 alkyl, (3) C2-18 alkenyl, (4) C2-18 alkynyl, (5) —COR (6) —CONR (7) —COOR (8) —SO (9) —COCOOR (10) —CONR (11) Cyc1 or (12) C1-18 alkyl, C2-18 alkenyl or C2-18 alkynyl substituted by 1-5 substituents selected from the group consisting of (a) halogen, (b) —CONR R (1) hydrogen, (2) C1-8 alkyl, (3) C2-8 alkenyl, (4) C2-8 alkynyl, (5) Cyc1 or (6) C1-8 alkyl, C2-8 alkenyl or C2-8 alkynyl substituted by 1-5 substituents selected from the group consisting of (a) Cyc1, (b) halogen, (c) —OR R 1) C2-6 alkylene, 2) —(C2-6 alkylene)-O—(C2-6 alkylene)-, 3) —(C2-6 alkylene)-S—(C2-6 alkylene)- or 4) —(C2-6 alkylene)-NR R (1) C1-8 alkyl, (2) C2-8 alkenyl, (3) C2-8 alkynyl, (4) Cyc1 or (5) C1-8 alkyl, C2-8 alkenyl or C2-8 alkynyl substituted by 1-5 substituents selected from the group consisting of (a) Cyc1, (b) halogen, (c) —OR R R 1) C2-6 alkylene, 2) —(C2-6 alkylene)-O—(C2-6 alkylene)-, 3) —(C2-6 alkylene)-S—(C2-6 alkylene)- or 4) —(C2-6 alkylene)-NR R Cyc1 is C3-15 mono-, bi- or tri-(fused or spiro)carbocyclic ring or 3-15 membered mono-, bi- or tri-(fused or spiro)cyclic hetero ring containing 1-4 nitrogen atoms, 1-3 oxygen atoms and/or 1-3 sulfur atoms, wherein Cyc1 may be substituted by 1-5 of R R (1) C1-8 alkyl, (2) C2-8 alkenyl, (3) C2-8 alkynyl, (4) halogen, (5) nitro, (6) trifluoromethyl, (7) trifluoromethoxy, (8) nitrile, (9) keto, (10) Cyc2, (11) —OR (12) —SR (13) —NR (14) —COOR (15) —CONR (16) —NR (17) —SO (18) —OCOR (19) —NR (20) —NR (21) —NR (22) —B(OR (23) —SO (24) —N(SO (25) —S(O)R (26) C1-8 alkyl, C2-8 alkenyl or C2-8 alkynyl substituted by 1-5 substituents selected from the group consisting of (a) halogen, (b) Cyc2, (c) —OR R 1) hydrogen, 2) C1-8 alkyl, 3) C2-8 alkenyl, 4) C2-8 alkynyl, 5) Cyc2 or 6) C1-8 alkyl, C2-8 alkenyl or C2-8 alkynyl substituted by Cyc2, —OR R 1) C2-6 alkylene, 2) —(C2-6 alkylene)-O—(C2-6 alkylene)-, 3) —(C2-6 alkylene)-S—(C2-6 alkylene)- or 4) —(C2-6 alkylene)-NR R 1) C1-8 alkyl, 2) C2-8 alkenyl, 3) C2-8 alkynyl, 4) Cyc2 or 5) C1-8 alkyl, C2-8 alkenyl or C2-8 alkynyl substituted by Cyc2, —OR R Cyc2 has the same meaning as Cyc1, wherein Cyc2 may be substituted by 1-5 of R R 1) C1-8 alkyl, 2) halogen, 3) nitro, 4) trifluoromethyl, 5) trifluoromethoxy, 6) nitrile, 7) —OR 8) —NR 9) —COOR 10) —SR 11) —CONR 12) C2-8 alkenyl, 13) C2-8 alkynyl, 14) keto, 15) Cyc6, 16) —NR 17) —SO 18) —OCOR 19) —NR 20) —NR 21) —NR 22) —SO 23) —N(SO 24) —S(O)R 25) C1-8 alkyl, C2-8 alkenyl or C2-8 alkynyl substituted by 1-5 substituents selected from the group consisting of (a) halogen, (b) —OR R R 1) C2-6 alkylene, 2) —(C2-6 alkylene)-O—(C2-6 alkylene)-, 3) —(C2-6 alkylene)-S—(C2-6 alkylene)- or 4) —(C2-6 alkylene)-NR R R 1) hydrogen, 2) C1-8 alkyl, 3) Cyc6 or 4) C1-8 alkyl substituted by Cyc6, R 1) C2-6 alkylene, 2) —(C2-6 alkylene)-O—(C2-6 alkylene)-, 3) —(C2-6 alkylene)-S—(C2-6 alkylene)- or 4) —(C2-6 alkylene)-NR Cyc6 is C3-8 mono-carbocyclic ring or 3-8 membered mono-cyclic hetero ring containing 1-4 nitrogen atoms, 1-2 oxygen atoms and/or 1-2 sulfur atoms, wherein Cyc6 may be substituted by 1-5 of R R (1) C1-8 alkyl, (2) halogen, (3) nitro, (4) trifluoromethyl, (5) trifluoromethoxy, (6) nitrile, (7) —OR (8) —NR (9) —COOR (10) —SR (11) —CONR R 1) hydrogen, 2) C1-8 alkyl, 3) phenyl or 4) C1-8 alkyl substituted by phenyl, R 1) C2-6 alkylene, 2) —(C2-6 alkylene)-O—(C2-6 alkylene)-, 3) —(C2-6 alkylene)-S—(C2-6 alkylene)- or 4) —(C2-6 alkylene)-NR R (1) hydrogen, (2) C1-8 alkyl, (3) C2-8 alkenyl, (4) C2-8 alkynyl, (5) —OR (6) Cyc3 or (7) C1-8 alkyl, C2-8 alkenyl or C2-8 alkynyl substituted by 1-5 substituents selected from the group consisting of (a) halogen, (b) —OR R 1) hydrogen, 2) C1-8 alkyl, 3) C2-8 alkenyl, 4) C2-8 alkynyl, 5) Cyc3 or 6) C1-8 alkyl, C2-8 alkenyl or C2-8 alkynyl substituted by Cyc3, R 1) C2-6 alkylene, 2) —(C2-6 alkylene)-O—(C2-6 alkylene)-, 3) —(C2-6 alkylene)-S—(C2-6 alkylene)- or 4) —(C2-6 alkylene)-NR 1) C1-8 alkyl, 2) C2-8 alkenyl, 3) C2-8 alkynyl or 4) Cyc3, or C1-8 alkyl, C2-8 alkenyl or C2-8 alkynyl substituted by Cyc3, Cyc3 has the same meaning as Cyc1, wherein Cyc3 may be substituted by 1-5 of R R (1) hydrogen, (2) C1-8 alkyl, (3) C2-8 alkenyl, (4) C2-8 alkynyl, (5) —COOR (6) —CONR (7) Cyc4 or (8) C1-8 alkyl, C2-8 alkenyl or C2-8 alkynyl substituted by 1-5 substituents selected from the group consisting of (a) halogen, (b) nitrile, (c) Cyc4, (d) —COOR R 1) hydrogen, 2) C1-8 alkyl, 3) C2-8 alkenyl, 4) C2-8 alkynyl, 5) Cyc4 or 6) C1-8 alkyl, C2-8 alkenyl or C2-8 alkynyl substituted by Cyc4, halogen, —OR R 1) C2-6 alkylene, 2) —(C2-6 alkylene)-O—(C2-6 alkylene)-, 3) —(C2-6 alkylene)-S—(C2-6 alkylene)- or 4) —(C2-6 alkylene)-NR R 1) C1-8 alkyl, 2) C2-8 alkenyl, 3) C2-8 alkynyl, 4) Cyc4 or 5) C1-8 alkyl, C2-8 alkenyl or C2-8 alkynyl substituted by Cyc4, halogen, —OR R R 1) C1-8 alkyl, 2) C2-8 alkenyl, 3) C2-8 alkynyl, 4) Cyc4 or 5) C1-8 alkyl, C2-8 alkenyl or C2-8 alkynyl substituted by Cyc4, R 1) hydrogen, 2) C1-8 alkyl, 3) C2-8 alkenyl, 4) C2-8 alkynyl, 5) Cyc4 or 6) C1-8 alkyl, C2-8 alkenyl or C2-8 alkynyl substituted by Cyc4, Cyc4 has the same meaning as Cyc1, wherein Cyc4 may be substituted by 1-5 of R R wherein R R (1) hydrogen, (2) C1-8 alkyl, (3) Cyc5 or (4) C1-8 alkyl substituted by Cyc5, wherein Cyc5 has the same meaning as Cyc1, and Cyc5 may be substituted by 1-5 of R R a quaternary ammonium salt thereof, an N-oxide thereof, or a non-toxic salt thereof.